Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × sotrastaurin × Clear all
NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Array BioPharma

Phase 1/2 Terminated
38 enrolled 31 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡